Design and In Vitro Evaluation of Chrono Modulated Theophylline Tablets

Authors

  • B Vijaya Kumar Jangaon Institute of Pharmaceutical Sciences, Jangaon, Warangal, (A.P), India
  • B Nagaraj University College of Pharmaceutical sciences, Kakatiya University, Warangal, (A.P), India
  • B Agaiah S.R.R. College of Pharmaceutical sciences. Valbhapur, Karimnagar (A.P), India
  • D Rambhau University College of Pharmaceutical sciences, Kakatiya University, Warangal, (A.P), India

DOI:

https://doi.org/10.3329/sjps.v1i1.1782

Keywords:

Theophylline, Chrono Modulated Drug Delivery, Asthma

Abstract

The objective of this research work was to prepare a chrono modulated delivery system to meet chronopharmacological needs of asthma. In this study theophylline was selected as a model drug. To meet this objective we considered an initial lag phase of release for 3-5 hrs and later a rapid (surge) release phase. To achieve surge release a rapidly releasing core tablet of theophylline was developed by admixing theophylline with effervescent granules and super disintegrants. The lag phase in release was achieved by coating the EV core tablets with release retarding polymer EUDRAGIT RS-100 containing HPMC, further over coated with enteric polymer CAP. The results indicate that a rapidly releasing EV tablet of theophylline cab be developed which when coated with the polymers a lag phase of 2 hrs was achievable followed by a surge release.

Key Words: Theophylline, Chrono Modulated Drug Delivery, Asthma.

doi:10.3329/sjps.v1i1.1782

S. J. Pharm. Sci. 1(1&2): 25-28

Downloads

Download data is not yet available.
Abstract
107
PDF
132

Downloads

How to Cite

Kumar, B. V., Nagaraj, B., Agaiah, B., & Rambhau, D. (2009). Design and In Vitro Evaluation of Chrono Modulated Theophylline Tablets. Stamford Journal of Pharmaceutical Sciences, 1(1), 25–28. https://doi.org/10.3329/sjps.v1i1.1782

Issue

Vol. 1 No. 1 (2008)

Section

Research Articles

License

As a condition of publication, all authors must transfer copyright to the Department of Pharmacy. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur in the submission, and that the final version of the manuscript has been seen and approved by them.

Each author must agree to this statement

Authorship: This manuscript is the original work of the authors, each of whom has read and approved of the work. Each author satisfied the requirements contained in 'Author Guidelines' having participated sufficiently in the work to take public responsibility for the content. This participation includes:

  • Conception or design of the study, or analysis and interpretation of data, or both
  • Drafting the article or revising it for critically important intellectual content
  • Approval of the final 'to be published' version

All authors must take responsibility for the integrity of the work. Participating solely in the collection of data does not justify authorship.

Prior publication: This work is not currently under consideration by any other journal. Information about prior publication of any part of this work, or inclusion of patients detailed herein in any other work, has been provided in the cover letter.

Conflict of interest: Details of any financial or other relationship between any author and any other party that may lead to a conflict of interest with the subject or any materials mentioned in this article have been disclosed in the cover letter.